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Background: Some male survivors of childhood cancer are suffering from azoospermia. In 
addition, spermatogonial stem cells (SSCs) are necessary for the improvement of spermatogenesis 
subsequent to exposure to cytotoxic agents such as cisplatin.
Objective: The aim of this study was to evaluate the anticancer activity of cisplatin-loaded folic 
acid-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) on mouse malignant 
cell line (EL4) and SSCs in vitro.
Methods: SSCs were co-cultured with mouse malignant cell line (EL4) cells and divided into 
four culture groups: 1) control (cells were co-cultured in the culture medium), 2) co-cultured cells 
were treated with cisplatin (10 µg/mL), 3) co-cultured cells were treated with cisplatin-loaded 
folic acid-conjugated PLGA NPs, and 4) co-cultures were treated with folic acid-conjugated 
PLGA for 48 hours. The NPs were prepared, characterized, and targeted with folate. In vitro 
release characteristics, loading efficiency, and scanning electron microscopy and transmission 
electron microscopy images were studied. Cancer cells were assayed after treatment using flow 
cytometry and TUNEL assay. The co-cultures of SSCs and EL4 cells were injected into semi-
niferous tubules of the testes after treating with cis-diaminedichloroplatinum/PLGA NPs.
Results: The mean diameter of PLGA NPs ranged between 150 and 250 nm. The number of 
TUNEL-positive cells increased, and the expression of Bax and caspase-3 were upregulated in 
EL4 cells in Group 4 compared with Group 2. There was no pathological tumor in testes after 
transplantation with treated co-cultured cells.
Conclusion: The PLGA NPs appeared to act as a promising carrier for cisplatin administration, 
which was consistent with a higher activation of apoptosis than free drug.
Keywords: spermatogonial cells, cancer cells, cisplatin, PLGA nanoparticles, drug delivery, 
folic acid
Introduction
Cancer is a disease distinguished by the uncontrolled growth and spread of abnormal 
cells and is still the second most common cause of death worldwide. Current treatment 
for cancer involves surgery, radiation, hormone therapy, and chemotherapy.1 The most 
frequent types of testicular cancer in the prepubertal age are pure teratomas and yolk 
sac tumors.2 In addition, acute lymphoblastic leukemia is detected in 34% of cancerous 
patients aged from 0 to 14 years.3 Spermatogenesis and male fertility are affected by 
whole-body radiation, radiation to the gonads, and alkylating chemotherapies because of 
their toxicity.4 One late effect of childhood cancer therapy is infertility which is seen in 
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15%–48% of male survivors. Sperm banking is an option for 
adult men before initiating treatment, but it cannot be used to 
preserve the fertility of prepubertal boys who do not have any 
sperm. This is a real health concern for males, while event-free 
survival rate of children with cancer is nearly 85%.5 Therefore, 
these patients can expect to have a normal productive life after 
treatment. There are hopeful stem cell research technologies 
(eg, spermatogonial stem cells [SSCs] transplantation),6–9 
testicular tissue grafting, testicular organ culture, and in vitro 
derivation of haploid gametes10 which are effective fertility 
options for these patients. Decontamination of preserved tes-
ticular tissue is a huge concern in cancer patients, as testicular 
biopsy in these patients could save the testicle tissues from 
malignant cells. Transplantation of leukemic cells alone or in 
SSC suspensions was found to impel shift of leukemia in the 
previous studies.11,12 Therefore, isolation of germ cells from 
malignant cells should be accomplished. Previous studies 
have shown that fluorescent-activated cell sorting (FACS)- 
or magnetic-activated cell sorting (MACS)-based methods 
can decontaminate malignant cells from heterogeneous 
testicular cell suspensions.12–18 However, decontamination 
of malignant cells by the abovementioned methods does not 
seem to be sufficient. Meanwhile, using a further method 
is necessary because even low levels of contamination can 
induce malignancy.11,12,19 Cisplatin is an important chemo-
therapeutic agent that is noted for its activity against testicu-
lar germ cell cancers. Cisplatin forms intra- and interstrand 
DNA cross-links, so it was suggested early that damage to 
DNA might be responsible for the therapeutic efficacy of 
cisplatin.20 However, there are severe side effects, particularly 
renal toxicity, associated with the usage of cisplatin.21 Con-
ventional chemotherapy is highly nonspecific in targeting 
the drug to tumoral cells due to simultaneous exposure of 
the chemotherapeutic agent to normal and cancerous cells. 
Therefore, no maximum dose of the drug is allowable for the 
treatment of tumoral cells.22 We have shown earlier that 
treatment with optimal and effective doses of cisplatin can 
be useful in the isolation of SSCs from tumoral cells.23 One 
of the further methods for the decontamination of cancerous 
cells from testicular cell suspensions can be used for smart 
drug delivery. Nanoparticles (NPs) are used as drug delivery 
vectors for targeting large doses of chemotherapeutic drugs 
or therapeutic genes into malignant cells, but they have a rare 
effect on healthy cells.22 Internalization of NPs into the cancer 
cells is enhanced due to positively charged surfaces and longer 
circulation times. Meanwhile, hydrophilic surfaces have modi-
fied enhancement of drug delivery to cancerous cells.24
Poly(lactic-co-glycolic acid) (PLGA) is one of the NP 
systems that can be used for cancer therapeutics due to its bio-
compatibility and biodegradability. In fact, PLGA undergoes 
hydrolysis in the body to produce the biodegradable 
metabolite monomers, lactic acid and glycolic acid, thus 
resulting in a minimal systemic toxicity.25 PLGA is approved 
by the US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) for use in different 
drug delivery systems in humans.26 Furthermore, the thera-
peutic efficacy of drug-loaded NPs is increased by targeted 
tumor-specific strategy. In this regard, folate receptor (FR) 
induction is one of the most hopeful strategies for smart 
targeting, and extensively utilized for drug targeting in 
epithelial cancers.27 Folate-conjugated nanocarriers have 
a high affinity and internalize into the cells via receptor-
mediated endocytosis. Furthermore, normal cells are able to 
transfer folic acid alone in a reduced form such as 5-methyl-
tetrahydrofolate, although they cannot transfer conjugated 
folate across their cell membrane.28 The influx of conjugated 
folates into the tumoral cells occurs mainly via the FRs, as 
these receptors are notably upregulated on cancerous cells 
compared with normal cells.29 Other advantages of folate/
PLGA are their high binding affinity, stability on storage and 
in circulation, and ease of conjugation to nanocarriers.28,30
For the potential clinical application of restoring fertility 
after anticancer therapy, and based on the promising data on 
sorting of SSCs from tumoral cells in previous reports, in this 
work we developed cisplatin-loaded folic acid-conjugated 
PLGA NPs to investigate elimination of EL4 cancer cells 
from SSCs, aiming to achieve a controlled inhibition of 
tumoral cell proliferation induced by drug delivery.
Experimental section
Materials
Cisplatin (cis-platinum diammine dichloride), PLGA 
(Resomer RG502H) with a 50:50 mole ratio of glycolic 
acid to lactic acid and a molecular weight of 12,000 g/mol, 
polyvinyl alcohol (PVA; 89 mol% hydrolyzed), Span 60 
(s7010), and Tween 60 (p1629) were purchased from Sigma 
(St Louis, MO, USA).
animals
In this experiment, 60 neonatal mice between 3 and 6 days old 
were used. These animals were obtained from the National 
Medical Research Institute (NMRI), originally taken from 
stocks of Razi Laboratory (Tehran, Iran). They were kept in 
cages made of plastic in a room at a temperature range of 
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22°C–25°C, with a 12-hour light/dark cycle. The research 
was approved by Research Ethics Committee of Iran 
University of Medical Sciences and was in accordance with 
the National Research Council guidelines (code: 21650).
co-culture of el4 cells and sscs
EL4 cell line and neonatal mouse SSCs were prepared, and 
the cultures were initiated as described earlier.23 The mouse 
acute lymphoblastic leukemia cell line EL4 was provided 
by the culture collection of Pasteur Institute, Tehran, Iran, 
and the isolation of SSCs from mice in this research was 
performed after obtaining ethical approval.
The SSCs co-cultured with testicular cell suspensions 
were contaminated with 5% EL4 cells at 37°C in a 5% CO
2
 
atmosphere in DMEM/F12 medium (Gibco) supplemented 
with 2% fetal bovine serum, penicillin (100 U/mL), strep-
tomycin (100 µg/mL), and gentamycin (40 µg/mL). In our 
previous study, the identity of the cultured cells was con-
firmed by the expression of specific markers (alpha-6-integrin 
and c-kit positive for SSCs and H-2Kb positive for EL4 
cells). In addition, functional transplantation assay for SSCs 
and tumorigenicity assays for EL4 cells were performed in 
recipient busulfan-treated testes.
experimental design
In this study, EL4 and SSCs were classified into four groups 
as follows: Group 1 was control (received medium); Group 2 
received blank NPs in the medium; Group 3 received an effec-
tive dose of cisplatin (10 µg/mL);23 and Group 4 received 
cisplatin-loaded folic acid-conjugated PLGA NPs.
Preparation and characterization of  
cisplatin-loaded Plga NPs
Preparation of nanocapsule containing cisplatin was performed 
using a modified water/oil/water (W/O/W) double-emulsion 
solvent evaporation procedure,31 with some modification. 
Briefly, cisplatin and distilled water (DW) mixture was pre-
pared by dissolving cisplatin in DW. This mixture was blended 
in dichloromethane (DCM) solution of the polymer (PLGA 
and Span 60) by ultrasonication for 45 seconds (power 50 W) 
in an ice bath to obtain a water-in-oil emulsion. Then, this 
emulsion was proximately dispensed into a 12 mL aqueous 
solution of PVA (2%, w/v) containing Tween 60, and the 
mixture was ultrasonicated again. The solvent exclusion of the 
final double emulsion (W/O/W) was carried out via vaporiza-
tion, and complete dispersion was done through mechanical 
stirring. For vaporization, the resulting double emulsion was 
diluted in an aqueous solution of PVA under mechanical 
stirring for a period of 3 hours at room temperature to allow 
the evaporation of DCM. Finally, drug-loaded NPs were col-
lected by centrifugation and washed three times with deionized 
water. The obtained nanocapsules were dried by freeze-drying 
and stored at 4°C. Blank NPs were prepared by the method 
described above except for the addition of cisplatin.
surface functionalization of cisplatin-
loaded Plga NPs with folate
In brief, folic acid was reacted with dicyclohexylcarbodiimide 
and N-hydroxysuccinimide (NHS) in DMSO with stirring. 
The activated folate was then reacted overnight with ethylene 
diamine in the presence of pyridine (0.2 mL) as a catalyst. 
The aminated folate (Fol-NH
2
) was precipitated out by adding 
excess of cold acetonitrile, followed by vacuum filtration. For 
conjugation of Fol-NH
2
 onto the surface of PLGA NPs, 10 mg 
of cisplatin-loaded NPs was dispersed in 5 mL of phosphate-
buffered saline (PBS; 0.02 M, pH 7.4), followed by addition 
of ethyl(dimethylaminopropyl) carbodiimide (EDC) and NHS 
to the above suspension. EDC activation was carried out by 
agitating the above suspension for 2 hours at room tempera-
ture using a magnetic stirrer. The excess of unreacted EDC 
and NHS was removed, and activated NPs were recovered 
by ultracentrifugation. The activated NPs were dispersed in 
PBS (0.02 M, pH 7.4), followed by the addition of Fol-NH
2
 
solution (1 mg/mL in PBS).32 The solution was again agitated 
at room temperature, and excess of unconjugated folate 
was removed by ultracentrifugation. The recovered folate-
conjugated NP suspension was lyophilized. Conjugation of 
folate onto PLGA NPs surface was confirmed by Fourier 
transform infrared spectroscopy (FTIR) analysis.
Determination of loading efficiency and 
in vitro release rate of cisplatin
Absorption measurements were performed to determine 
the amount of drug encapsulated in PLGA using UV–vis 
spectrophotometer (model UV-1650 PC; Shimadzu Europe, 
Tokyo, Japan). First, 5 mg of the dry PLGA nanocapsules 
was dissolved in 1 mL DCM. Then, 1 mL of PBS (pH 7.4) 
was added. For precipitating polymer phase from aqueous 
phase, centrifugation was performed at 10,000 rpm for 20 
min. The drug loading of this solution was determined by 
measuring the absorption peak at 300 nm with a UV–vis 
spectrophotometer, and quantitatively determined by 
comparison with a previously established standard curve. 
The concentration of cisplatin was investigated using Beer’s 
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law. The results of the experiment are expressed as the aver-
age of three different analyses.
 
Encapsulation efficiency, EE
Amount of encapsulated 
cis
(%) =
platin (mg) in nanocapsule 
Initial amount (mg) of 
cisplatin used in the recipe 
×100
 
In addition, for determining the in vitro release of cispla-
tin from NPs, 5 mg of nanocapsule powder was suspended 
in 5 mL of PBS (pH 7.4). The suspension was incubated at 
37°C. The tubes were centrifuged at definite time intervals. 
After centrifugation, the supernatants were collected for the 
determination of cisplatin, analyzed using the UV–vis spec-
trophotometer by measuring the absorption peak at 300 nm, 
and replaced by the same quantity of fresh PBA solution. The 
tubes were then placed back in the incubator.
Particle size analysis and zeta potential 
measurement
The particle size of the nanocapsules was determined by 
dynamic light scattering (DLS) on a Nano-ZS system (Model 
ZEN3600; Malvern Instruments, Malvern, UK) using a zeta 
sizer. In brief, 1 mg/mL of NP suspension was prepared 
in MilliQ water, and sonicated for 30 seconds over an ice 
bath using a sonicator (with 50 W energy output) to avoid 
the formation of large aggregates. The zeta potential of the 
nanoformulations was determined by the same instrument, 
following the above protocol, before and after folate conjuga-
tion. All measurements were performed in triplicates.
Transmission electron microscopy (TeM) 
and scanning electron microscopy (seM)
The NPs were evaluated for size by TEM (LEO 906; Carl 
Zeiss). After sonicating for 5 min, one drop of NP suspen-
sion (1 mg/mL) was placed on a carbon-coated copper TEM 
grid and dried in the open air before negative staining with 
uranyl acetate solution (1%). Size and surface morphology 
of nanocapsules were investigated by SEM with Vega-II 
from Tescan Co. (Brno, Czech Republic). The samples for 
SEM analysis were put under vacuum and sputter-coated 
with gold.
FTIr analysis
The infrared spectra of cisplatin, PLGA, folic acid, and 
cisplatin-loaded folate-conjugated PLGA NPs were 
recorded using a Fourier transform infrared spectropho-
tometer (FTIR-ATR-Perkin Elmer 2000). The spectra of 
all the materials were recorded at a frequency range of 
500–4,000 cm−1 and averaged over four runs. The powdered 
samples were placed on the attenuated total reflectance crys-
tal, and then compressed using an axial screw.
In vitro cellular cytotoxicity assay
MTT assay was performed to evaluate the toxicity of blank 
NPs and cisplatin-loaded PLGA NPs and that of free cisplatin 
against EL4 cancer cells and SSCs separately. The cells 
(5 × 103 per well) were seeded in 96-well plates. After treat-
ing with various concentrations of NPs (0.5, 1, and 2 mg/mL) 
and 10 µg/mL free cisplatin for 48 hours, the culture medium 
was removed and 10 µL/well MTT solution (5 mg/mL) was 
added, plates were incubated at 37°C for 3 hours, and then 
the medium was replaced with 100 µL of DMSO to dis-
solve the formazan crystals. The absorbance was measured 
at 570 nm using a microplate reader. The experiments were 
performed three times.
In situ cell death detection of el4 cells 
following treatment
EL4 cells (5,000 per well) were incubated with 10 µg/mL 
cisplatin and cisplatin-loaded PLGA NPs. After 48 hours 
of incubation, apoptosis was detected by TUNEL assay. 
TUNEL staining was carried out using an In-Situ Cell Death 
Detection Kit (Roche, Basel, Switzerland) according to the 
provided protocol.
Determination of apoptotic and 
antiapoptotic gene expression following 
treatment by quantitative reverse 
transcription Pcr (qrT-Pcr)
The effect of free cisplatin and cisplatin-loaded PLGA NPs 
on Bax, bcl2, and caspase-3 gene level in EL4 cells was 
investigated by real-time quantitative PCR analysis. Briefly, 
EL4 cells were incubated with 10 µg/mL concentrations of 
cisplatin and 2 mg/mL of NPs for 48 hours. Total mRNA 
was isolated, and real-time PCR amplification of cDNAs was 
performed following the protocol. The relative quantifica-
tion of gene expression was performed using GAPDH as an 
internal control.
Determination of cell percentage of sscs 
and EL4 cells using flow cytometry after 
co-culture
After co-culture of SSCs and EL4 cells with 10 µg/mL 
concentration of cisplatin, blank NPs, and cisplatin-loaded 
PLGA NPs for 48 hours, the cells were incubated with 
an FITC-conjugated mouse anti-H-2Kb monoclonal 
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antibody (553569; Pharmingen) at 1:50 concentration and 
phycoerythrin-conjugated rat anti-CD49f monoclonal anti-
body (ab95703; Abcam, Cambridge, UK) (concentration of 
1:10) for 20 min at 4°C in the dark.
In vivo evaluation of decontamination of 
sscs from el4 cells after treatment
After adding the cisplatin-loaded PLGA NPs to the co-
cultured cells, the mixture of cells was transferred to the 
recipient busulfan-treated NMRI mice’s efferent ductuli33 
(6–8 weeks, male, 20–30 g body weight) to evaluate the 
tumor efficacy. After 2 months, their abdomen was evaluated 
for the presence of tumors, and the testes were isolated and 
prepared for histological evaluation as described earlier.23
statistical analysis
All quantitative data derived from this study were analyzed sta-
tistically and presented as mean ± SD. Statistical significance 
was determined using the one-way ANOVA test, followed by 
the post hoc Tukey’s test. The cell percentages determined 
using flow cytometry were compared using an independent 
t-test. P-values less than 0.05 were considered significant.
Results
Physiochemical characterization of  
cis-diaminedichloroplatinum (cDDP)/
Plga NPs
The release of cisplatin from the prepared nanocapsules was 
evaluated in a PBS release medium with a pH of 7.4 at 37°C. 
The drug release was determined at definite intervals up to 
7 days. The resulting curves exhibited a biphasic drug release 
pattern that was characterized by an initial rapid phase fol-
lowed by a slower, continuous-release phase during 1 week 
(Figure 1A). The release of cisplatin from NPs was slightly 
faster in the first 48 hours; during this period, 70% of cisplatin 
was released. After 168 hours of incubation, about 97% of 
cisplatin was released from the CDDP/PLGA NPs at pH 7.4. 
The loading efficiency of cisplatin was calculated from the 
amount of recovered cisplatin from each batch relative to the 
initial amount of cisplatin used in the preparation process, and 
it was found to be about 78% ± 2.1%. The release of drugs 
from folate-conjugated NPs almost mimicked the pattern of 
unconjugated NPs release (data not shown). DLS analysis 
revealed that the NPs had a mean hydrodynamic diameter 
of 235 ± 7.3 nm with a polydispersity index of 0.585 and a 
negative zeta potential of −9 to −14.5 mV (Figure 1B). These 
negative values were due to the ionization of carboxyl groups 
on the surface of the nanocapsules. The surface modifica-
tion of PLGA-NPs with folate had no significant effect on 
their size characteristics; however, zeta potential changed to 
2.6 ± 0.8 mV which indicated the presence of folic acid. The 
conjugation of folate to PLGA NPs and loading of the drug 
were confirmed by FTIR analysis, and the peaks at 1,475, 
1,274, and 1,170 cm−1 in folate-functionalized NPs clearly 
indicated the formation of amide bond following conjugation 
(Figure 1C). The small new peaks at 800 and 1,626 cm−1 seen in 
cisplatin-loaded NPs proved the presence of the drug in NPs.
seM and TeM observations
The SEM images showed the outer surface of nanocapsules. 
It was obvious that the nanocapsules had a smooth surface 
and were sphere-shaped (Figure 1D). The micrographs 
obtained from the TEM analysis gave some information 
about the structure, internal morphology, particle size, and 
distribution of the nanocapsules. Figure 1E shows the TEM 
micrographs of the CCDP/PLGA sample, which illustrates 
the spherical structure of the nanocapsules with the particle 
size in the range of 150–250 nm and their sizes consistent 
with DLS results. Indeed, no aggregation of nanocapsules 
was found while they were discrete due to negative surface 
charge according to zeta potential results.
assessment of cytotoxicity of cDDP/
Plga NPs, free cisplatin, and blank NPs 
on el4 and sscs
The cytotoxicity of CDDP/PLGA NPs, free cisplatin, and 
blank NPs on SSCs and EL4 cell lines was investigated 
using MTT assays (Figure 2A–D). As shown in Figure 2C, 
both cell lines were treated with varying concentrations of 
0.5, 1, and 2 mg/mL of CDDP/PLGA and blank NPs and 
10 µg/mL of free cisplatin for 48 hours on the basis of a 
previous study (time and dose of drug). To determine the 
best effect of NPs on the elimination of tumoral cells, cell 
viability was evaluated 48 hours following exposure with 
free cisplatin. The EL4 survival rates were found to be about 
37.57% ± 0.55%, 32.79% ± 0.39%, and 25.42% ± 0.36% at 
the concentrations of 0.5, 1, and 2 mg/mL of CDDP/PLGA 
NPs, respectively. However, SSCs survival rates were found 
to be about 78.50% ± 1.34%, 71.34% ± 0.46%, and 60.74% ± 
0.44% at the concentrations of 0.5, 1, and 2 mg/mL of CDDP/
PLGA NPs, respectively. As shown in Figure 2C, the viabili-
ties of EL4 cells and SSCs treated with 0.5, 1, and 2 mg/mL 
of blank NPs were similar to those of the control group (no 
significant difference) at all tested concentrations in 48 hours, 
revealing the low toxicity and biocompatibility of the 
copolymers to the cells. As shown in Figure 2D, 2 mg/mL 
concentration of CDDP/PLGA NPs and free cisplatin were 
compared to each of the cell lines. The EL4 IC
50
 and SSCs 
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IC
50
 for the group that received the effective dose of cisplatin 
(10 µg/mL) were 8 and 6.5 µg/mL, respectively. However, 
the survival rate of tumor cells that received 2 mg/mL of 
NPs was 25.42% ± 3.6% for EL4 cells and 66.04% ± 1.6% 
for SSCs.
comparison of el4 apoptosis between 
free cisplatin and cDDP/Plga NPs
The apoptotic characteristics of the cancer cells in the group 
that received free cisplatin compared with the group that 
received NPs are shown in Figure 3. We selected random 
fields per sample and counted approximately 80 cells for each 
group. The number of TUNEL-positive EL4 cells increased 
to about 41.8 ± 1.6 with 10 µg/mL cisplatin treatment after 
48-hour incubation. The treatment with 2 mg/mL of CDDP/
PLGA NPs significantly increased apoptosis by 45.2% ± 1.2% 
compared to free cisplatin. These results indicated that a 
higher number of TUNEL-positive cells were undergoing 
apoptosis upon cisplatin treatment (p  0.05). In addition, 
we treated EL4 cells with 10 µg/mL cisplatin and 2 mg/mL 
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Figure 1 Physiochemical characterization and seM and TeM analyses of cDDP/Plga NPs.
Notes: (A) sustain-release phenomenon exhibited by drug-loaded NPs in PBs with ph of 7.4 at 37°c. Initially, 30% of cisplatin was released, and after 48 hours, 70% of 
cisplatin was released. The values are shown as mean ± sD, n = 3. (B) size of NPs was measured by Dls. (C) FTIr spectrum of cDDP/Plga NPs. (D) scanning electron 
micrographs of cisplatin-loaded Plga NPs prepared with W/O/W method (bar: 1 µm). The blue h’s represent the width of the nanoparticles. (E) TeM analysis of drug-
loaded NPs depicting the spherical nature of the nanocapsules (bar: 570 nm). The red arrows represent a completely dark center and the blue arrows show the bright margin 
of the nanoparticle, indicating the loaded drug and the environmental polymer.
Abbreviations: seM, scanning electron microscopy; TeM, transmission electron microscopy; cDDP, cis-diaminedichloroplatinum; Plga, poly(lactic-co-glycolic acid); 
NPs, nanoparticles; PBs, phosphate-buffered saline; Dls, dynamic light scattering; FTIr, Fourier transform infrared spectroscopy; W/O/W, water/oil/water.
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cisplatin-loaded PLGA NPs for 48 hours, and examined the 
apoptotic gene expression by qRT-PCR. The expression of 
BAX and caspase-3 was increased in the group that received 
NPs after 48 hours of incubation compared with that in the 
group that received free cisplatin (Figure 3G and I). The 
results clearly showed a significant decrease in the expression 
of bcl-2 in the cells treated with 2 mg/mL CDDP/PLGA NPs 
compared with that in free cisplatin group (Figure 3H). The 
results clearly indicated an overexpression of the apoptotic 
gene and downregulation of antiapoptotic gene following 
the cisplatin treatment.
comparison sscs and el4 cells 
percentage determined by flow 
cytometry after treatment
The percentage of SSCs and EL4 in the co-culture was assayed 
by flow cytometry after treatment. The percentage of cells 
that expressed CD49f (alpha-6-integrin) was on an average of 
59.64 ± 2.5 and the percentage of cells that expressed H-2Kb 
marker was about 0.8 ± 0.14 in the group that received folic 
acid-conjugated CDDP/PLGA NPs, whereas the percentage of 
SSCs and EL4 cells was 39.43 ± 6.33 and 1.90 ± 0.17, respec-
tively, in the group that received free cisplatin (p  0.05). 
There was no significant difference in the percentage of SSCs 
and EL4 cells in the group that received blank NPs compared 
with the control group (Figure 4).
In vivo evaluation of sscs 
decontamination from el4 cells after 
treatment with cDDP/Plga NPs
As mentioned, the co-culture of SSCs and EL4 cells was 
injected into the seminiferous tubules of the testes after 
treating with CDDP/PLGA NPs. No testes or seminiferous 
tubules tumor was observed in the histological sections 
8 weeks after transplantation. Also, we observed DiI-labeled 
SCC proliferation and regional colonization of stem cells 
(Figure 5). Furthermore, SCCs transplantation improved 
the condition and structure of the seminiferous tubules in 
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Figure 2 sscs and el4 cells shape and cytotoxicity analyses.
Notes: (A) a colony of sscs (bar = 100 µm). (B) el4 cell line (bar = 100 µm). (C) cytotoxicity study of 0.5, 1, and 2 mg/ml of cDDP/Plga and blank NPs (0.5, 1, and 2 mg/ml) 
and 10 µg/mL of free cisplatin after 48-hour incubation with EL4 cells and SSCs as determined by the MTT assay (a): there is a significant difference between the experimental 
groups compared with the control and blank NPs group (p  0.05), and (b): there is a significant difference between the groups in relation to each other that received 
different doses of cisplatin-loaded Plga NPs (p  0.05). (D) comparison of 2 mg/ml concentration of cDDP/Plga NP and free cisplatin on the cell lines. as shown by the 
calibration curve for the release of the drug, the results obtained are confirmed by the results of the evaluation of cell survival with MTT.
Abbreviations: sscs, spermatogonial stem cells; cDDP, cis-diaminedichloroplatinum; Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles.
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the busulfan-azoospermia model, indicating that spermato-
genesis began in many seminiferous tubules.
Discussion
At present, there is no way to preserve the fertility of 
prepubertal cancer patients after cancer therapy.12,34 After 
exposure to a chemotherapeutic drug such as cisplatin, the 
seminiferous epithelium becomes dysfunctional due to direct 
damage to the germ cells and apoptosis, and thus cannot 
provide optimal support.35 SCC transplantation may be a 
hopeful method, but the possible contamination with cancer-
ous cells is the main barrier.9,12,36 The therapeutic efficacy 
of cisplatin may be limited due to its poor water solubility 
and high affinity of binding to plasma proteins and degrad-
ability.37 Therefore, the goal is to overcome the limitations 
of conventional chemotherapy, which include undesirable 
biodistribution, cancer cell cisplatin resistance, and severe 
systemic side effects. Use of NPs is promising due to their 
ability of targeted delivery.38
Here, we describe a novel approach for the elimination of 
cancerous cells from SSCs by treatment with cisplatin-loaded 
PLGA NPs in comparison with free cisplatin treatment. 
As reported above, PLGA NPs production was carried out 
using W/O/W double-emulsion solvent evaporation method 
to obtain well-rounded PLGA NPs with high encapsulation 
efficiency (up to 78%). Our results showed that the burst 
release within the first 2 hours was similar to that observed 
in previous studies.39 It may be due to linking with cisplatin 
which just adsorbed on the outer surface of the NPs. 
An example showing the initial burst and linear release 
was also reported.40 The characteristic PLGA zeta-potential 
reached 2.6 mV after surface modification by folic acid. 
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Figure 3 TUNel assay for el4 cells treated with free cisplatin and 2 mg/ml of cDDP/Plga NPs and comparison of the mrNa levels of apoptosis-related genes in the el4 
cells treated with cisplatin (10 µg/ml) and 2 mg/ml of cisplatin-loaded Plga NPs for 48 hours.
Notes: The green cells indicate the TUNel-positive apoptotic cells. It can be seen that the number of apoptotic cells increased after 48 hours in the group treated with 2 mg/
ml cDDP/Plga NPs: (A) TUNel assay; (B) DaPI staining; and (C) merged. comparison with free cisplatin: (D) TUNel assay; (E) DaPI staining; and (F) merged. activated 
gene expression of (G) Bax and (I) caspase-3. (H) Downregulation of antiapoptotic gene, bcl2. each value represents mean ± sD, and the experiments were carried out in 
triplicate. *p  0.05 as compared with el4 cells that were treated with 2 mg/ml of cisplatin-loaded Plga NPs. Bar = 100 µm.
Abbreviations: cDDP, cis-diaminedichloroplatinum; Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles.
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In general, cisplatin-loaded PLGA NPs have been success-
fully designed and spherical particles prepared, and narrow 
size distribution has been characterized. A sustained release 
of cisplatin over 4 days from folic acid-conjugated PLGA 
NPs in vitro was observed. The results of the characterization 
of cisplatin-loaded PLGA NPs supported previous investi-
gations in which NPs were prepared using similar methods. 
The pH- or temperature-induced rapid drug release rates and 
thus high drug efficacy and theoretically rapid cytoplasmic 
drug release can be achieved if the NPs can dissolve in the 
acidic endosomes or lysosomes and then rapidly rupture their 
membranes. However, these NPs become soluble at pH close 
to 7, and thus, destabilize and release drugs in the slightly 
acidic extracellular spaces of solid tumors.41 But our NPs 
formulation did not respond to a particular stimulus and the 
release of drug depended on controlled polymer degradation. 
Actually, in our research, we determined the rate of polymer 
degradation and the amount of drug released at a time, and 
loaded a certain dose of the drug to provide a specific drug 
concentration for the treatment of the target cells. The results 
indicated that the mean size of the PLGA NPs was about 
197 nm as determined by TEM, and the release was 62.4% 
at 72 hours according to the in vitro release study. Finally, 
no significant toxic effects were observed with empty NPs, 
using the equivalent amount in milligrams of loaded NPs.39
The survival rate of tumor cells treated with 2 mg/mL 
folic acid-conjugated CDDP/PLGA NPs after 48 hours 
of incubation was about 25%. However, SSCs had over 
60% viability compared with the tumor cell survival of 
approximately 50% in the group that received an effective 
dose of cisplatin (10 µg/mL). The IC
50
 of CDDP/PLGA 
NPs (2 mg/mL) was significantly higher than that observed 
with free cisplatin. No toxicity of blank NPs on SSCs was 
observed, which mimicked the findings of our previous study 
with a different particle.42
Due to the retention of the complex in the primary emul-
sion phase, cisplatin can be loaded into the NPs made of 
hydrophobic PLGA with hydrophilic methoxide polyethyl-
ene glycol chains.39 With the evaporation of the solvent at 
ambient conditions, our particles had a spherical internal 
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Figure 4 Flow cytometry analysis of surface markers (cD49f positive for sscs and h-2Kb positive for el4 cells): (A) el4 + sscs suspension, (B) el4 + sscs suspension 
treated with blank NPs, (C) el4 + sscs suspension treated with 10 µg/ml cisplatin, and (D) el4 + sscs suspension treated with 2 mg/ml cisplatin-loaded NPs.
Abbreviations: sscs, spermatogonial stem cells; NPs, nanoparticles.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
22
5.
18
7.
12
5 
on
 1
4-
Se
p-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2952
shabani et al
P
$ % &
' ( )
* + ,
P P
PP
PP P
P
Figure 5 In vivo tumor histological examination and evaluation of decontamination of sscs from el4 cells after treatment with cDDP/Plga NPs.
Notes: (A) histological analysis of busulfan-treated control mice. (B) Normal seminiferous tubules are seen in the group that received el4 cells and sscs after treatment. 
(C) histological section of tumor formed from el4 cells alone stained with h&e (bar = 100 µm). cell labeling of sscs and transplantation. (D) a cluster of sscs labeled with 
DiI, (E) cells labeled with DaPI, and (F) merged. Bar = 100 µm. (G–I) colonization and proliferation of labeled injected cells (bar = 50 µm).
Abbreviations: sscs, spermatogonial stem cell; cDDP, cis-diaminedichloroplatinum; Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles.
structure. This shape seemed to be due to the persistence of 
cisplatin, while the shell of the particles was dark, consistent 
with the PLGA matrix. The results suggested that cisplatin 
was dispersed inside the PLGA nanocapsules. There was a 
difference in our findings between the sizes reported by DLS 
and electron microscopy. That is why, a higher hydrodynamic 
diameter of NPs was determined by DLS analysis compared 
with that detected by TEM and SEM analyses and contributed 
to the hydration of the surface-associated PVA. Our results 
demonstrated a higher fraction of apoptotic cell death in 
EL4 cells treated by cisplatin-loaded folic acid-conjugated 
PLGA NPs than that by free drug in solution. It is notable 
that cisplatin-entrapped NPs enhanced the apoptotic activity 
compared with cisplatin treatment, due to the maximum 
activity achieved with folic acid-conjugated NPs. The for-
mulation also showed an enhanced therapeutic ability over 
free cisplatin as the NPs were targeted to the cancerous cells 
by folic acid in a similar way as shown in previous studies.32 
A marked increase in apoptosis was found through the major 
effector caspase-3 by cisplatin-loaded PLGA NPs after 48 
hours of incubation. Cisplatin activates apoptosis as it is a 
heavy metal compound and causes inhibition of DNA replica-
tion and transcription, by producing DNA cross-links. These 
modifications result in DNA damages that, in turn, block 
cell cycle causing apoptosis, finally leading to the activa-
tion of caspases cascade.43 TUNEL assay also confirmed 
the enhanced effectiveness of cisplatin-loaded NPs on EL4 
cancerous cells. In a previous study on ovarian cancer cells, it 
was demonstrated that the number of TUNEL apoptotic cells 
in cisplatin-loaded PLGA NPs group increased compared 
with the ones that received cisplatin.37
Geens et al demonstrated that FACS and MACS purifica-
tion is not sufficiently efficient to ensure a total depletion of 
malignant cells from a germ cell suspension and it induced 
leukemia in the recipients.12 Our results seem to contradict 
this promising report; however, a major problem is low effi-
ciency of this cell-sorting technique because of low cancer 
cells detection. Although we were not able to entirely delete 
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tumoral EL4 cells from SSCs, we did not find induced tumor 
in the recipients after the treatment for smart drug delivery. 
It appears from our results that more research on alternative 
decontamination techniques is necessary until the depletion 
of malignant cells reaches zero. Furthermore, the surface 
of NPs could have affected cisplatin delivery to cancerous 
cells while conjugated with the H-2Kb antibody (anti-EL4 
cells). This recent method may be utilized for targeting 
applications or gene delivery to induce apoptosis as a novel 
cancer therapy.
Conclusion
We conclude that cisplatin-loaded PLGA NPs have a sig-
nificant effect on the elimination of tumoral cells from germ 
cells. Hence, we observed a controlled release of cisplatin 
from NPs as compared with free cisplatin. Our findings 
confirm that cisplatin-loaded NPs can serve as a novel tool 
for the isolation of SSCs from cancerous cells. A targeted 
delivery of cisplatin will improve the therapeutic efficacy of 
the drug and will be useful for decontamination of cancer 
cells. Overall, the results of this study suggest that cisplatin-
loaded PLGA NPs induce apoptosis in EL4 cancer cells. 
Also, NP-mediated cisplatin delivery may further improve 
the therapeutic efficacy of free cisplatin.
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